Amneal Pharmaceuticals, Inc (AMRX) 2024 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Thank you for your patience, everyone. The Amneal Pharmaceuticals fourth-quarter 2024 earnings conference call will begin shortly. (Operator Instructions)

    感謝各位的耐心等候。Amneal Pharmaceuticals 2024 年第四季財報電話會議即將開始。(接線員指示)

  • Good morning and welcome to the Amneal Pharmaceuticals fourth-quarter 2024 earnings conference call.

    各位早安,歡迎參加 Amneal Pharmaceuticals 2024 年第四季財報電話會議。

  • I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony Dimeo. Please go ahead.

    現在我想把電話會議交給 Amneal 投資人關係主管 Tony Dimeo。請開始。

  • Anthony Dimeo - Head-Investor Relations

    Anthony Dimeo - Head-Investor Relations

  • Good morning and thank you for joining Amneal Pharmaceuticals fourth-quarter 2024 earnings call. Today, we issued a press release reporting Q4 results. The earnings press release and presentation are available at amneal.com.

    各位早安,感謝各位參加 Amneal Pharmaceuticals 2024 年第四季財報電話會議。今天我們已發布新聞稿,報告第四季業績。財報新聞稿與簡報可於 amneal.com 取得。

  • Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us. Please see this section entitled, Cautionary Statements, on forward-looking statements for factors that may impact future performance.

    本次電話會議中,針對非歷史事實事項所作的若干陳述(包括但不限於管理層的展望或預測)屬於前瞻性陳述,且僅以目前我們可取得的資訊為基礎。請參閱「前瞻性陳述之警示聲明」章節,了解可能影響未來表現的因素。

  • We also discussed non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation.

    我們也將討論非 GAAP 衡量指標。關於這些指標的使用資訊以及與 GAAP 的調節,均載於財報新聞稿與簡報中。

  • On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs; Tasos Konidaris, CFO; our Commercial Leaders, Andy Boyer for Affordable Medicines and Joe Renda for Specialty; and Jason Daly, Chief Legal Officer.

    今天與會者包括共同創辦人暨共同執行長 Chirag Patel 與 Chintu Patel;財務長 Tasos Konidaris;我們的商務領導團隊:平價藥品事業的 Andy Boyer 與專科事業的 Joe Renda;以及法務長 Jason Daly。

  • I will now hand the call over to Chirag.

    現在我把電話會議交給 Chirag。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Tony. Good morning, everyone. At Amneal, we're much more than another generics company. We are an American biopharmaceutical company with a track record of excellence in delivering high-quality complex pharmaceuticals at speed and scale. We are a leader in an essential industry, providing millions of patients with access to affordable and innovative medicines.

    謝謝你,Tony。各位早安。在 Amneal,我們遠不只是另一家學名藥公司。我們是一家美國生物製藥公司,長期以來以速度與規模提供高品質的複雜藥品,成績卓著。我們是這個關鍵產業的領導者,讓數以百萬計的病患得以取得可負擔且具創新性的藥物。

  • 2024 was an exceptional year where Amneal delivered stellar financial performance with double-digit revenue and adjusted EBITDA growth and reducing net leverage below 4 times. All segments grew revenues double digits. This broad-based performance reflects the strength of our diversified business, strong execution, and continued investment in growth areas. Beyond financial results, we took major strategic steps in 2024 to enhance our long-term growth profile and expand our future potential, including launching CREXONT, establishing our GLP-1 collaboration, and adding to our biosimilars pipeline.

    2024 年是表現卓越的一年,Amneal 交出亮眼的財務成果:營收與調整後 EBITDA 皆達雙位數成長,並將淨槓桿降至 4 倍以下。所有事業部門的營收皆呈雙位數成長。這種全面性的表現反映了我們多元化業務的韌性、強勁的執行力,以及對成長領域的持續投資。除了財務成果之外,2024 年我們也採取多項重大策略行動,以強化長期成長輪廓並擴大未來潛力,包括推出 CREXONT、建立我們的 GLP-1 合作,以及擴充生物相似藥產品線。

  • The first important milestone we achieved in 2024 was the successful launch of CREXONT. We are so excited by the strong response from prescribers and inspiring patient testimonials. Early traction has exceeded expectations, with market share reaching about 1% in just four months and on track to exit the year at 3% plus. As a point of reference, RYTARY has 6% market share currently 10 years since its launch. We are very confident in achieving U.S. peak sales of $300 million to $500 million for CREXONT.

    我們在 2024 年達成的第一個重要里程碑,是成功推出 CREXONT。我們對處方醫師的強烈回饋以及令人振奮的病患見證感到非常興奮。早期動能超出預期,僅四個月市占率即達約 1%,並有望在年底前達到 3% 以上。作為參考,RYTARY 自上市 10 年以來,目前市占率為 6%。我們非常有信心,CREXONT 在美國的峰值銷售可達 3 億至 5 億美元。

  • Our Specialty business grew 14% in 2024, and our goal is to grow Specialty to over $500 million by 2027. This growth will be driven by CREXONT, UNITHROID, ONGENTYS, and upcoming launch of DHE and other branded products. We aim to add more branded opportunities to our portfolio over time.

    我們的專科事業在 2024 年成長 14%,目標是在 2027 年前將專科事業營收提升至超過 5 億美元。此成長將由 CREXONT、UNITHROID、ONGENTYS,以及即將推出的 DHE 與其他品牌產品所帶動。我們也將隨時間推進,持續為產品組合增加更多品牌機會。

  • Second, in 2024, we entered the high-growth weight loss and obesity space, a new category for Amneal through a strategic collaboration with Metsera, a clinical stage biotech company developing next-generation therapies. This unique collaboration represents a new integrated business model to drive innovation at scale between two organizations. It is a logical extension of Amneal's strategy that leverages our expertise in complex manufacturing and track record of delivering high-quality innovation at scale.

    第二,2024 年我們透過與臨床階段生技公司 Metsera 的策略合作,進入高成長的減重與肥胖領域,這對 Amneal 而言是一個新的類別;Metsera 正在開發下一代療法。這項獨特的合作代表一種新的整合式商業模式,讓兩個組織能以規模化方式推動創新。這也是 Amneal 策略的合理延伸,運用我們在複雜製造方面的專業,以及以規模提供高品質創新的實績。

  • Ameal is Metsera's preferred global supplier for the U.S., Europe, and other markets. In addition, we look to commercialize Metsera products in 20 emerging markets, including India. To support this effort, we will leverage our existing peptide capabilities and building two new high-volume peptide manufacturing facilities. With the global weight loss market projected to exceed $150 billion by 2030, this initiative is a powerful new long-term growth driver for Amneal. Over time, we see this as a very large opportunity for Amneal with three avenues for value creation. One, the Metsera collaboration which is our top priority. Two, providing CMO offerings to other large companies. Three, providing skill to deliver on generic weight loss therapies.

    Ameal 是 Metsera 在美國、歐洲及其他市場的首選全球供應商。此外,我們也計畫在包含印度在內的 20 個新興市場商業化 Metsera 的產品。為支持此一工作,我們將運用既有的胜肽能力,並興建兩座新的高產量胜肽製造設施。在全球減重市場預計於 2030 年前超過 1,500 億美元的背景下,這項計畫將成為 Amneal 強而有力的全新長期成長動能。隨著時間推進,我們認為這對 Amneal 是一個非常龐大的機會,並有三條價值創造途徑。第一,Metsera 的合作案,這是我們的首要優先事項。第二,向其他大型公司提供 CMO 服務。第三,提供能力以交付學名減重療法。

  • Third, our Affordable Medicine segment historically referred to as Generics, includes retail products and our rapidly growing injectable and biosimilar products. The Affordable Medicines segment generated revenues of $1.7 billion in 2024 as growth accelerated to 15%, fueled by new launches and a diversified complex portfolio over three components of the segment. This is a massive business that remains the foundation of Amneal. And we expect it will continue to grow tremendously going forward.

    第三,我們的平價藥品事業部門(歷來稱為學名藥)包含零售產品,以及快速成長的注射劑與生物相似藥產品。平價藥品事業在 2024 年創造 17 億美元營收,成長加速至 15%,主要受新產品上市與涵蓋該事業三大組成的多元化複雜產品組合所帶動。這是一項龐大的業務,仍是 Amneal 的基石。我們預期未來它將持續大幅成長。

  • Within this segment, our injectable business is expanding quickly. We have a growing portfolio of over 40 injectable products and launched our first three 505(b)(2) injectables in 2024. These differentiated ready-to-use solutions improve hospital efficiency by eliminating medication preparation steps and errors. In addition, we see biosimilars as the next major wave of affordable medicines. For patients, biosimilars improve the affordability of and access to key therapies.

    在此事業部門中,我們的注射劑業務正快速擴張。我們擁有超過 40 項注射劑產品的持續擴增產品組合,並於 2024 年推出首三項 505(b)(2) 注射劑產品。這些具差異化的即用型解決方案,透過消除用藥準備步驟與錯誤,提升醫院效率。此外,我們認為生物相似藥將是下一波平價藥品的重大浪潮。對病患而言,生物相似藥可提升關鍵療法的可負擔性與可近性。

  • For Amneal, we see biosimilars as a long-term growth factor where we are well-positioned to lead. Our first three biosimilars generated $126 million revenue in 2024, just their second year on the market. We have built our pipeline with five additional biosimilars expected to be filed this year and commercial launches planned for 2026 and 2027. In 2024, we added our largest opportunity, omalizumab, a biosimilar for XOLAIR, targeting $2.8 billion U.S. market. By 2027, we expect to have six commercial biosimilars in the United States market. Looking forward, the global biosimilar is projected to grow from about $33 billion today to $75 billion by 2030.

    對 Amneal 而言,我們將生物相似藥視為長期成長因素,而我們具備領先的有利位置。我們的前三項生物相似藥在 2024 年創造 1.26 億美元營收,這僅是它們上市的第二年。我們已建立產品線,另有五項生物相似藥預計於今年提出申請,並規劃於 2026 年與 2027 年商業上市。2024 年,我們新增了最大機會:omalizumab(XOLAIR 的生物相似藥),鎖定 28 億美元的美國市場。到 2027 年,我們預期在美國市場將有六項已商業化的生物相似藥。展望未來,全球生物相似藥市場預計將從目前約 330 億美元成長至 2030 年的 750 億美元。

  • Given the cost, complexity, and development pipelines, we see a relatively limited number of market participants. A recent IQVIA report highlighted the significant white space opportunity in biosimilars. There are over 100 biologic products with patents expiring over the next 10 years and only 10% currently have biosimilars in development. The report estimates that biosimilars for the other 90% would save American patients about $100 billion per year.

    鑑於成本、複雜度與研發產品線等因素,我們認為市場參與者的數量相對有限。近期一份 IQVIA 報告凸顯了生物相似藥顯著的「白地」機會。未來 10 年將有超過 100 項生物製劑專利到期,但目前僅有 10% 正在開發生物相似藥。該報告估計,若其餘 90% 也推出生物相似藥,將可為美國病患每年節省約 1,000 億美元。

  • We believe success in biosimilars will be driven by product selection, speed to market, R&D, manufacturing, and customer service. Similar to complex generics where Amneal is a leader, we are well-positioned to be a major biosimilar player. Our strategic focus has been in licensing and initial portfolio and building a commercial platform to start. Next, our goal is to be vertically integrated and leverage our proven ability to develop, manufacture, and commercialize complex pharmaceuticals at scale.

    我們相信,生物相似藥的成功將取決於產品選擇、上市速度、研發、製造以及客戶服務。類似於 Amneal 在複雜學名藥領域的領先地位,我們具備成為主要生物相似藥業者的有利條件。我們的策略重點一直在於授權引進與初始產品組合,並先行建立商業化平台。接下來,我們的目標是實現垂直整合,並運用我們在大規模開發、製造與商業化複雜藥品方面已被驗證的能力。

  • Finally, our avKARE segment is a highly durable business with long-term contracts and recurring revenue streams across three channels: Distribution, government, and unit dose. In 2024, avKARE revenue grew 25% and we expect continued double-digit growth, reaching over $900 million in revenue by 2027. This business adds stability and diversification to Amneal's portfolio.

    最後,我們的 avKARE 事業部是一項高度耐久的業務,擁有長期合約,並透過三個通路帶來經常性收入:配送、政府與單位劑量(unit dose)。2024 年,avKARE 營收成長 25%,我們預期將持續維持雙位數成長,並在 2027 年前達到超過 9 億美元的營收。此業務為 Amneal 的產品組合增添穩定性與多元化。

  • Overall, Amneal is an essential player in an essential industry. Over 90% of prescriptions in the United States are for affordable medicines, yet account for only 10% of commercial value. Amneal fulfills over 162 million scripts for American patients each year. We are the largest U.S. manufacturer of affordable medicines. Currently, Amneal is number four in the U.S. retail market based on value. And our goal is to become top five in the U.S. injectables and U.S. biosimilars market in coming years. Over our company's history, we have built a successful track record of innovation, execution, and growth. Amneal is uniquely positioned in the pharmaceutical industry with a broad and differentiated portfolio across affordable medicines, specialty, and distribution to drive sustainable growth.

    整體而言,Amneal 是一個關鍵產業中的關鍵參與者。美國超過 90% 的處方為可負擔藥品,但其商業價值僅占 10%。Amneal 每年為美國病患提供超過 1.62 億張處方。我們是美國最大的可負擔藥品製造商。目前,按價值計算,Amneal 在美國零售市場排名第四。我們的目標是在未來幾年成為美國注射劑與美國生物相似藥市場的前五大業者。在公司發展歷程中,我們建立了創新、執行與成長的成功紀錄。Amneal 在製藥產業中具備獨特定位,擁有涵蓋可負擔藥品、專科用藥與配送的廣泛且差異化產品組合,以推動可持續成長。

  • I'll now pass it to Chintu.

    我現在把時間交給 Chintu。

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Chirag. And good morning, everyone. And special thanks to our dedicated employees for making Amneal a purpose-driven company focused on execution and delivering value to our stakeholders. Today, I will provide an update on our strategic priorities across operations, innovation, and our portfolio.

    謝謝你,Chirag。各位早安。也特別感謝我們敬業的員工,讓 Amneal 成為一家以使命為導向、專注於執行並為利害關係人創造價值的公司。今天,我將就我們在營運、創新以及產品組合方面的策略優先事項提供最新進展。

  • First, our world-class global operations remain a key competitive advantage. Amneal has standard quality track record and a world-class operational infrastructure with an extensive manufacturing footprint in the United States, Ireland, and India. Over our history, the FDA has conducted over 105 successful inspections with either no or only minor observations. Further, we continue to invest in digitization, automation, and operational efficiencies to drive innovation and growth across different dosage forms. We are committed to enhancing our operational excellence and cost efficiencies across our global infrastructure amidst chronic drug shortages and supply chain challenges in the U.S., Amneal stands out with its industry-leading quality, resilient supply chain, and high customer fulfillment rates.

    首先,我們世界級的全球營運仍是關鍵競爭優勢。Amneal 擁有穩健的品質紀錄與世界級的營運基礎設施,並在美國、愛爾蘭與印度擁有廣泛的製造據點。在我們的歷史中,FDA 已完成超過 105 次成功稽查,且未發現或僅有輕微觀察事項。此外,我們持續投資數位化、自動化與營運效率,以推動不同劑型的創新與成長。在美國長期藥品短缺與供應鏈挑戰之下,我們致力於提升全球基礎設施的營運卓越與成本效率;Amneal 以業界領先的品質、具韌性的供應鏈以及高客戶履約率脫穎而出。

  • A key highlight is our collaboration with Metsera in the GLP-1 space where our partner's portfolio is moving swiftly through the drug development phase. Amneal already has the infrastructure and capabilities for peptide development and injectable manufacturing. As part of this collaboration, we will build two state-of-the-art manufacturing facilities, one for peptide drug substance production and another for advanced sterile field finish manufacturing. These investments will enable large scale production, positioning Amneal as Metsera's preferred global supplier while leveraging our R&D expertise and quality leadership in this fast growing category.

    一項重點亮點是我們與 Metsera 在 GLP-1 領域的合作,我們合作夥伴的產品組合正快速推進藥物開發階段。Amneal 已具備胜肽開發與注射劑製造的基礎設施與能力。作為此合作的一部分,我們將興建兩座最先進的製造設施,一座用於胜肽原料藥(drug substance)生產,另一座用於先進無菌充填完成(sterile fill-finish)製造。這些投資將支持大規模生產,使 Amneal 成為 Metsera 首選的全球供應商,同時運用我們在此快速成長類別中的研發專長與品質領導地位。

  • Next in innovation, we launched CREXONT which is a remarkable new treatment for Parkinson's disease designed for rapid onset and extended efficacy. CREXONT delivers more (inaudible) time with fewer doses. Our open label Phase 4 study is underway to generate additional real-world evidence. We are pleased with early adoption and wonderful testimonials from patients positioning CREXONT to become the leading branded Parkinson's therapy.

    接著在創新方面,我們推出了 CREXONT,這是一種針對帕金森氏症的卓越新療法,旨在快速起效並延長療效。CREXONT 以較少的劑量提供更多(聽不清)時間。我們的開放標籤第 4 期研究正在進行中,以產生更多真實世界證據。我們對早期採用情況以及病患的精彩見證感到滿意,這使 CREXONT 有望成為領先的品牌帕金森氏症治療。

  • Next in our Specialty pipeline is the DHE autoinjector for migraine and cluster headache. The innovative presentation of a well-known molecule is intended to help patients avoid emergency room visits during these painful episodes. We project peak sales of $50 million to $100 million and look forward to launch later this year pending FDA approval.

    接下來,在我們的專科用藥研發管線中,有用於偏頭痛與叢集性頭痛的 DHE 自動注射器。這種對已知分子所做的創新劑型呈現,旨在協助病患在這些疼痛發作期間避免前往急診。我們預估其峰值銷售額為 5,000 萬至 1 億美元,並期待在今年稍晚、待 FDA 核准後上市。

  • Next, I will touch on our complex generics portfolio. We expect to launch 20 to 30 new products each year. This year, so far, we have launched key complex products such as mesalamine, everolimus, and memantine/donepezil which has $180 billion exclusivity. Last week, we received approval for lenalidomide which we'll launch in early 2026. This cadence of approvals and new launches reflects the breadth and depth of our R&D pipeline.

    接下來,我將談談我們的複雜學名藥產品組合。我們預期每年推出 20 到 30 項新產品。截至目前,今年我們已推出關鍵複雜產品,例如美沙拉嗪(mesalamine)、依維莫司(everolimus)以及美金剛/多奈哌齊(memantine/donepezil),其具有 1,800 億美元的獨占期。上週,我們取得來那度胺(lenalidomide)核准,預計於 2026 年初上市。這樣的核准與新上市節奏,反映出我們研發管線的廣度與深度。

  • Currently, we have 76 products pending approval, of which, 61% are non-oral solids and 56% in development, of which, 93% are non-oral solids. We continue to optimize our R&D portfolio allocating more resources towards biosimilars and Specialty over time. In 2024, we launched 12 new injectable products including our first three 505(b)(2) products, PEMRYDI, FOCINVEZ for oncology, and potassium phosphate ready-to-use IV bag. Our fourth 505(b)(2) injectable, BORUZU, for multiple myeloma is approved and set to launch in Q2 with 10 to 12 additional 505(b)(2) injectables in development. We will meaningfully expand our injectable portfolio.

    目前,我們有 76 項產品待核准,其中 61% 為非口服固體劑型;另有 56% 正在開發中,其中 93% 為非口服固體劑型。我們持續優化研發產品組合,並隨時間將更多資源配置至生物相似藥與專科用藥。2024 年,我們推出 12 項新的注射劑產品,包括我們前三項 505(b)(2) 產品:PEMRYDI、用於腫瘤科的 FOCINVEZ,以及即用型磷酸鉀靜脈輸液袋。我們第四項 505(b)(2) 注射劑 BORUZU(用於多發性骨髓瘤)已獲核准,預計於第二季上市,另有 10 至 12 項 505(b)(2) 注射劑正在開發中。我們將大幅擴充注射劑產品組合。

  • Other complex injectable programs, microsphere, liposomals, and drug combinations are progressing as well. With our R&D capabilities and infrastructure of 21 manufacturing lines and injectables, Amneal is well-positioned to be a leader in the injectable space in the coming year.

    其他複雜注射劑計畫,如微球、脂質體以及藥物組合,也在推進中。憑藉我們的研發能力,以及 21 條製造產線與注射劑基礎設施,Amneal 已具備在未來一年成為注射劑領域領導者的有利條件。

  • In biosimilar, we are strategically focused on expanding our portfolio. We are very excited about the biosimilar market given the upcoming wave of biologics LOEs, clarity on the regulatory pathway, and continued adoption by clinicians.

    在生物相似藥方面,我們策略性地聚焦於擴大產品組合。鑑於即將到來的一波生物製劑專利到期(LOE)、法規途徑的明確性,以及臨床醫師持續採用,我們對生物相似藥市場感到非常振奮。

  • Building on the success of our first three commercial products, we have inlicensed five additional biosimilar pipeline candidates. The BLA filings for two denosumab biosimilars were submitted. Next, the supplemental BLA filing for peg-filgrastim, OBI, and autoinjector is expected in Q2. After that, the BLA filing for omalizumab, a biosimilar for XOLAIR, is expected by the end of the year. We need to further expand our portfolio and be vertically integrated over time to be a leader in the biosimilar industry.

    在我們前三項商業化產品成功的基礎上,我們已授權引進另外五項生物相似藥研發管線候選產品。兩項地舒單抗(denosumab)生物相似藥的 BLA 申請已提交。接下來,針對 peg-filgrastim 的補充 BLA 申請(含 OBI 與自動注射器)預計於第二季提出。之後,針對奧馬珠單抗(omalizumab)(XOLAIR 的生物相似藥)的 BLA 申請預計於年底前提出。我們需要進一步擴大產品組合,並隨時間推進垂直整合,以成為生物相似藥產業的領導者。

  • In summary, we are focused on driving execution across development, manufacturing, and commercialization throughout our diversified and growing business.

    總結而言,我們專注於在開發、製造與商業化各環節推動執行力,貫穿我們多元化且持續成長的業務。

  • With that, I will hand it over to Tasos.

    接下來,我把時間交給 Tasos。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Thank you, Chintu. And good morning, everyone. 2024 was a very strong year of execution across all our business units with excellent financial performance well ahead of our original guidance metrics. In addition, net leverage declined to 3.9 times compared to 4.8 times at the end of 2023. As we grew EBITDA and we pay down debt strategically, as Chirag and Chintu highlighted, we are driving the ongoing diversification of the business through new launches and pipeline expansion in biosimilars and GLP-1s which provides a strong foundation for long-term growth. In 2025, we expect continued cap and bottom line growth reflecting our ability to offset RYTARY of exclusivity due to the breadth and depth of our commercial portfolio and strong pipeline.

    謝謝你,Chintu。各位早安。2024 年我們在所有事業單位的執行力都非常強勁,財務表現也明顯優於我們原先的指引指標。此外,淨槓桿倍數降至 3.9 倍,相較於 2023 年底的 4.8 倍。隨著 EBITDA 成長並策略性償還債務,正如 Chirag 與 Chintu 所強調,我們正透過生物相似藥與 GLP-1 產品的新上市與研發管線擴充,推動業務持續多元化,為長期成長奠定堅實基礎。展望 2025 年,我們預期營收與獲利將持續成長,反映我們憑藉商業產品組合的廣度與深度以及強勁的研發管線,有能力抵銷 RYTARY 失去獨家權的影響。

  • I'll review our strong performance in Q4, touch on our full-year results, and discuss guidance for 2025.

    我將回顧我們第四季的強勁表現,簡要說明全年成果,並討論 2025 年的指引。

  • In the fourth quarter, revenues of $731 million grew 18% with double-digit growth across all three segments. Our Affordable Medicines segment grew 21% to $439 million. New product launches added $54 million to Q4 revenue driven by recent complex launches. Biosimilars generated $39 million in Q4 revenues and grew 49% versus the prior year.

    第四季營收為 7.31 億美元,成長 18%,三大事業部皆呈現雙位數成長。我們的平價藥品(Affordable Medicines)事業部成長 21% 至 4.39 億美元。新產品上市為第四季營收貢獻 5,400 萬美元,主要由近期複雜產品上市所帶動。生物相似藥第四季營收為 3,900 萬美元,較去年同期成長 49%。

  • As Chintu mentioned, Amneal's continued success in R&D, superb quality track record, and supply consistency are competitive advantages driving sustainable growth, portfolio diversification, and value to customers, providers, and patients.

    如 Chintu 所提,Amneal 在研發上的持續成功、卓越的品質紀錄與穩定供應,是我們的競爭優勢,推動可持續成長、產品組合多元化,並為客戶、醫療提供者與病患創造價值。

  • Q4 Specialty revenues grew 16% to $121 million driven by our branded products. Our Parkinson's franchise, which includes CREXONT, RYTARY, and ONGENTYS generated $64 million in Q4 revenues, including $3 million for CREXONT. As we said, we're very pleased with the initial launch success of CREXONT and its early trajectory well ahead of RYTARY's launch.

    第四季專科(Specialty)營收成長 16% 至 1.21 億美元,主要由我們的品牌產品帶動。我們的帕金森氏症產品線(包含 CREXONT、RYTARY 與 ONGENTYS)第四季營收為 6,400 萬美元,其中 CREXONT 貢獻 300 萬美元。如先前所述,我們對 CREXONT 初期上市的成功非常滿意,其早期走勢明顯優於 RYTARY 當年上市時的表現。

  • In Q4, our AvKARE segment grew 14% to $170 million, reflecting continued growth across the distribution and government channels. New product launches and continued strong execution are key drivers of AvKARE's strong performance.

    第四季 AvKARE 事業部營收成長 14% 至 1.70 億美元,反映在通路分銷與政府渠道的持續成長。新產品上市與持續強勁的執行力,是 AvKARE 優異表現的關鍵驅動因素。

  • Moving down the P&L, Q4 adjusted EBITDA of $155 million reflects robust revenue growth, consistent growth margins, and some targeted R&D in sales and marketing investments in high growth areas. Q4 adjusted EPS of $0.12 declined $0.02 as higher adjusted EBITDA was offset by interest expense.

    往下看損益表,第四季調整後 EBITDA 為 1.55 億美元,反映強勁的營收成長、穩健的毛利率,以及在高成長領域進行部分針對性的研發與銷售及行銷投資。第四季調整後每股盈餘(EPS)為 0.12 美元,下降 0.02 美元,因較高的調整後 EBITDA 被利息費用所抵銷。

  • In summary, Q4 reflected strong year-over-year revenue growth of 18% and adjusted EBITDA growth of 9%.

    總結而言,第四季呈現 18% 的年增營收成長,以及 9% 的調整後 EBITDA 成長。

  • Moving on to the full year of 2024, total revenues were $2.8 billion, up $400 million or 17% year-over-year. It was ahead of our original and revised guidance of about $2.6 billion. Each segment through double digits with Affordable Medicines up 15%, Specialty up 14%, and AvKARE up 25%.

    接著看 2024 全年,總營收為 28 億美元,年增 4 億美元或 17%。此表現高於我們原始與修正後約 26 億美元的指引。各事業部皆為雙位數成長:平價藥品成長 15%,專科成長 14%,AvKARE 成長 25%。

  • 2024 adjusted gross margins were strong at 42.4% with Affordable Medicines gross margins expanding by 110 basis points, reflecting new product launches and operating efficiencies. Full-year 2024 adjusted EBITDA of $627 million was ahead of original guidance of $580 million to $620 million and grew 12% which includes a substantial increase in R&D and social marketing to enhance our already strong pipeline and support new launches.

    2024 年調整後毛利率維持強勁,為 42.4%;其中平價藥品毛利率擴張 110 個基點,反映新產品上市與營運效率提升。2024 全年調整後 EBITDA 為 6.27 億美元,高於原先 5.80 億至 6.20 億美元的指引,並成長 12%;其中包含研發與社群行銷的大幅增加,以強化我們本已強勁的研發管線並支持新產品上市。

  • From a cash flow perspective, 2024 operating cash flow was $348 million, excluding one-time legal costs, well ahead of original guidance of $260 million to $300 million. This strong performance was driven by higher adjusted EBITDA and good work by our teams to drive substantial working capital improvements and some timing benefits.

    從現金流角度來看,2024 年營運現金流為 3.48 億美元(不含一次性法律費用),明顯優於原先 2.60 億至 3.00 億美元的指引。這項強勁表現主要來自較高的調整後 EBITDA,以及團隊推動大幅營運資金改善與部分時點上的有利因素。

  • I'm also glad to report that as part of our efforts to reduce leverage, we pay down $182 million of gross debt in 2024 and reduced net leverage to 3.9 times as compared to 4.8 times at the end of 2023. And going further back, 7.4 times net leverage at the end of 2019. We achieved net leverage below 4 times one year ahead of our publicly stated target.

    我也很高興報告,作為我們降低槓桿努力的一部分,我們在 2024 年償還了 1.82 億美元的總債務,並將淨槓桿倍數降至 3.9 倍,相較於 2023 年底的 4.8 倍。再往前回顧,2019 年底淨槓桿倍數為 7.4 倍。我們比對外公開的目標提前一年達成淨槓桿低於 4 倍。

  • In summary, very strong full-year 2024 results with revenue growth of 18%, adjusted EBITDA of 12%, and substantial debt reduction while continuing to invest for long-term growth.

    總結而言,2024 全年成果非常強勁:營收成長 18%、調整後 EBITDA 成長 12%,並在持續投資長期成長的同時大幅降低債務。

  • Let me now move on and discuss our full-year guidance for 2025. On the top line, we expect 2025 total company net revenue of $3.0 billion to $3.1 billion, reflecting strong growth of 7% to 11%.

    接下來我將討論 2025 年的全年指引。在營收方面,我們預期 2025 年公司合併淨營收為 30 億至 31 億美元,反映 7% 至 11% 的強勁成長。

  • First, in the Affordable Medicines segment, we expect continued double-digit growth in 2025 due to the uptake of products launched throughout 2024. Some new launches expected in 2025, continued by a similar growth in injectables expansion with a number of new 505(b)(2) products.

    第一,在平價藥品事業部,我們預期 2025 年將持續雙位數成長,主要來自 2024 年全年上市產品的放量。2025 年也預期會有部分新上市產品,並在多項新的 505(b)(2) 產品帶動下,注射劑擴張將延續類似的成長。

  • Second, in the Specialty segment, we expect 2025 revenue of approximately $400 million which includes expected CREXONT sales of approximately $50 million and expected RYTARY sales between $120 million to $140 million given the loss of exclusivity in the third quarter of 2025.

    第二,在專科事業部,我們預期 2025 年營收約 4 億美元,其中包含 CREXONT 預期銷售約 5,000 萬美元,以及考量 2025 年第三季失去獨家權後,RYTARY 預期銷售介於 1.20 億至 1.40 億美元。

  • Third, in the AvKARE segment, we expect continued double-digit growth in 2025 driven by ongoing new launches from Amneal and other suppliers across its channels.

    第三,在 AvKARE 事業部,我們預期 2025 年將持續雙位數成長,動能來自 Amneal 與其他供應商在各渠道持續推出新產品。

  • Moving down the P&L, we expect 2025 adjusted gross margins between 41% and 42%, similar to 2024. We expect adjusted EBITDA between $650 million and $675 million, reflecting growth between 4% to 8% due to top line growth, the RYTARY loss of exclusivity, as well as incremental sales and marketing investments to maximize the substantial commercial opportunity ahead of us, that is CREXONT, biosimilars, 505(b)(2)s, and injectables.

    往下看損益表,我們預期 2025 年調整後毛利率介於 41% 至 42%,與 2024 年相近。我們預期調整後 EBITDA 介於 6.50 億至 6.75 億美元,反映 4% 至 8% 的成長,主要受營收成長、RYTARY 失去獨家權,以及為最大化我們面前龐大的商業機會而增加的銷售與行銷投資所影響;這些機會包括 CREXONT、生物相似藥、505(b)(2) 產品與注射劑。

  • From an EPS perspective, we expect 2025 adjusted EPS between $0.65 and $0.70, which reflects adjusted EBITDA growth and lower interest expense as debt levels have been reduced and interest rates are beginning to come down.

    在每股盈餘方面,我們預期 2025 年調整後 EPS 介於 0.65 至 0.70 美元,反映調整後 EBITDA 成長,以及隨著債務水位下降與利率開始下行而帶來的較低利息費用。

  • Moving to cash flow, we expect another strong year of cash generation in 2025 which allows us to continue reducing gross debt and net leverage. For 2025, we expect operating cash flow excluding potential legal settlement costs between $280 million and $310 million. Depending on timing of settlements, we may incur approximately $25 million of costs which are substantially lower than prior years.

    在現金流方面,我們預期 2025 年將再度呈現強勁的現金創造能力,使我們得以持續降低總債務與淨槓桿。2025 年,我們預期不含潛在法律和解成本的營運現金流介於 2.80 億至 3.10 億美元。視和解時點而定,我們可能產生約 2,500 萬美元成本,顯著低於前幾年。

  • From a capital allocation perspective, we continue to prioritize investments to further diversify our business and drive sustainable growth, particularly high growth areas such as specialty, biosimilars, and GLP-1s. In 2025, we expect capital expenditures of approximately $100 million net of reimbursement related to the facilities we're building as part of our Metsera collaboration. In addition, we continue to be laser focused in continuing to reduce our debt levels.

    在資本配置方面,我們仍優先投入以進一步多元化業務並推動可持續成長,特別是專科、生物相似藥與 GLP-1 等高成長領域。2025 年,我們預期資本支出約 1 億美元(已扣除與我們與 Metsera 合作、正在興建之設施相關的補償款)。此外,我們也將持續高度聚焦於進一步降低債務水位。

  • Looking to the balance sheet, our strong financial performance and disciplined capital allocation is driving higher cash generation and continued delevering. Recognizing our delevering progress and improved financial profile, we're pleased to receive one (inaudible) upgrades from S&P and Moody's a few months ago.

    從資產負債表來看,我們強勁的財務表現與嚴謹的資本配置,正推動更高的現金創造能力並持續去槓桿。鑑於我們去槓桿的進展與改善的財務概況,我們很高興在幾個月前獲得標普與穆迪各一次(聽不清)調升評等。

  • Now that net leverage is below 4 times, our focus is on driving net leverage to below 3 times in the next few years.

    現在淨槓桿已低於4倍,我們的重點是在未來幾年將淨槓桿降至3倍以下。

  • Let me now turn the call back to Chirag.

    我現在把電話會議交回給Chirag。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Tasos. In summary, 2024 was a remarkable year for Amneal. We delivered broad-based double-digit growth and took key strategic actions to further position our company for sustainable long-term growth. Amneal enters a new chapter of growth in 2025 with tremendous momentum across our business. And we are so excited for what's ahead.

    謝謝你,Tasos。總結來說,2024年對Amneal而言是非凡的一年。我們實現了廣泛的雙位數成長,並採取關鍵策略行動,進一步讓公司站穩可持續的長期成長定位。Amneal在2025年以全業務的強勁動能,開啟新的成長篇章。我們對未來的一切都感到非常興奮。

  • Let's now open the call for Q&A.

    現在我們開放問答環節。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Chris Schott, JPMorgan.

    JPMorgan的Chris Schott。

  • Christopher Schott - Analyst

    Christopher Schott - Analyst

  • Great. Thanks so much for the questions. Maybe just to start off with, I just had a couple on CREXONT. Can you just elaborate on these first few months of the launch? It seems like the ramp's going really nicely. But I was wondering is there any surprises from perspective in terms of either where the patients are coming from or just any dynamics of how physicians are integrating this into their practices? And maybe just a second one on CREXONT while we're at it, can you just give us the latest in terms of where formulary access stands and how you're seeing that trending?

    太好了。非常感謝讓我提問。我想先從CREXONT談起,我有幾個問題。能否請你們進一步說明上市最初這幾個月的情況?看起來放量進展相當順利。但我想了解,從病患來源或醫師如何把它整合進臨床實務的動態來看,有沒有任何出乎意料之處?另外,既然談到CREXONT,能否也請你們更新一下目前處方集(formulary)准入的最新狀況,以及你們觀察到的趨勢?

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Chris. We're so excited beyond our expectations. And the patient testimonials are amazing. This is where you feel so good that the patient that wasn't able to walk now walks. They're taking fewer capsules a day, lasting longer. So it's arguably right now, it's only four months, it's performing as the best CD/LD formulation and absorption ever seen in this category. And this is straight from the most well-known KOL saying it's the best absorption he has seen and he called it a miracle drug. And we keep hearing that from all across the MDS, even started from general neuro.

    謝謝你,Chris。我們的興奮程度超出預期。而且病患的見證非常令人驚豔。這讓你感覺非常好:原本無法行走的病患現在能走路了。他們每天服用的膠囊數更少、藥效維持更久。所以可以說,就目前而言,雖然才四個月,它的表現可說是此類別中所見過最佳的CD/LD配方與吸收效果。這是直接來自最知名的KOL,他說這是他見過最好的吸收,甚至稱之為奇蹟藥物。我們也在各地的MDS那裡不斷聽到同樣的回饋,甚至從一般神經科開始也是如此。

  • We're going after the long term care, so we're covering all corners of the market now, all 100%. Where (inaudible) we covered only 20% which is the (inaudible) market with MDS. We have broadened our market reach. The teams are doing great. We're so excited. There's already 1,000-plus prescriptions per week just in four months. It would have taken two years to get there. So amazing feedback. Formulary access is awesome as well. And to discuss that further, I'll pass it on to Joe Renda, our Head of Specialty Business.

    我們正在拓展到長期照護領域,因此現在我們覆蓋市場的各個角落,達到100%全面覆蓋。過去(聽不清)我們只覆蓋20%,也就是(聽不清)由MDS主導的市場。我們已擴大市場觸及範圍。團隊執行得非常好。我們非常興奮。在短短四個月內,每週處方量已超過1,000張。這在過去可能需要兩年才能達到。所以回饋非常驚人。處方集准入也非常出色。為了進一步說明,我把問題交給我們專科事業部負責人Joe Renda。

  • Joe Renda - Senior Vice President, Chief Commercial Officer-Specialty

    Joe Renda - Senior Vice President, Chief Commercial Officer-Specialty

  • Thanks, Chris, for the question. And yeah, to Chirag's point, we're very pleased with the performance we've seen thus far. The team has really executed well the plan. The response from the market has been remarkable. We continue to hear from physicians literally every day the patient responses that they're getting. You asked about formulary access and so far, we've been very pleased with the response from the payers. Right now, we're somewhere in the neighborhood of about 30% coverage rate. We anticipate that to go up this year in the neighborhood of 50%. Our goal has always been to catch or surpass RYTARY coverage which is around 70%.

    謝謝你,Chris,謝謝這個問題。是的,呼應Chirag的觀點,我們對目前看到的表現非常滿意。團隊確實把計畫執行得很好。市場反應非常亮眼。我們幾乎每天都會從醫師那裡聽到他們所觀察到的病患反應。你問到處方集准入,到目前為止,我們對付款方的回應非常滿意。目前我們的覆蓋率大約在30%左右。我們預期今年會提升到約50%左右。我們的目標一直是追上或超越RYTARY的覆蓋率,大約在70%左右。

  • We anticipate bringing on at least one, two, maybe even three major commercial payers this year. So the coverage conversations have been very good. The payers are also seeing the demand generation that's happening in the market, so that's further exciting them about bringing CREXONT on formulary. And we're also getting great response from the advocacy organizations. So we're partnering very closely with the advocacy organizations across the country. They're also helping spread the word of how favorable CREXONT has been. So just to give you a point of illustration, when you look at the way CREXONT has performed in launch versus RYTARY, we're 3 to 5 times where RYTARY was at this point in launch. So very good uptake in the market, very pleased, and we look for more to come.

    我們預期今年至少會新增一到兩家,甚至可能三家主要商業保險付款方。因此覆蓋率的洽談進展非常順利。付款方也看到市場端正在發生的需求拉動,這也讓他們更有興趣把CREXONT納入處方集。此外,我們也獲得倡議組織非常好的回應。因此我們正與全國各地的倡議組織密切合作。他們也在協助傳播CREXONT表現優異的訊息。舉例來說,若比較CREXONT與RYTARY在上市初期的表現,我們目前是RYTARY在同一時間點的3到5倍。因此市場採用度非常好,我們非常滿意,也期待後續還會有更多進展。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • And Chris, last thing I would add is this, we're making CREXONT a global product, so creating global access. So we have a partner in Canada, South America, Mexico. We are a partner in Europe. A new market in India. And we're looking for a partner in China and Japan. So this would be a truly global product. As you know, RYTARY was never available outside of United States. Millions of Parkinson's patients across the globe and this will be the best therapy that they will get for their day-to-day living with Parkinson's.

    Chris,我最後再補充一點:我們正把CREXONT打造為全球性產品,建立全球准入。因此我們在加拿大、南美、墨西哥都有合作夥伴。在歐洲也有合作夥伴。在印度是一個新市場。我們也正在尋找中國與日本的合作夥伴。因此這將會是一個真正的全球性產品。如你所知,RYTARY從未在美國以外上市。全球有數以百萬計的帕金森氏症病患,而這將是他們日常生活中能獲得的最佳療法。

  • Christopher Schott - Analyst

    Christopher Schott - Analyst

  • Excellent. And maybe just one last question for me, just a bigger picture with the strong top line, you thinking about either organic investment into the business or external BD any differently than the past? I'm just trying to get a sense of how you're thinking about balancing longer term investment and top line growth versus the drop through of that growth in terms of the near term margins. Thank you.

    非常好。我最後一個問題,從更宏觀的角度來看,在營收端表現強勁的情況下,你們對於業務的內生成長投資或外部商務開發(BD)的思考,是否會與過去有所不同?我想了解你們如何在長期投資與營收成長,和這些成長在短期利潤率上的落地(drop-through)之間取得平衡。謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thanks, Chris. So we're so fortunate to have a solid organic pipeline in affordable medicines. So we've been affordable medicines and the retail GX. We have a leading portfolio in inhalation, ophthalmics, microsphere. Just drug device combination products. So one of the best portfolio we have. Then comes to the injectable which we have 12 or so more 505(b)(2) injectables to come, ready-to-use, peptide, microspheres. Very excited. Biosimilars, we have in-licensed the product as we've been very upfront about it that this is -- and very long-term focused that this is over 10 years business, it is, and we've been investing for a long time. We need to become vertically integrated. So have manufacturing with us, R&D with us, full pipeline, global market. And just like in complex GX, we're here to stay. Our mission is to become America's number one affordable medicines company. So biosimilar expansion is a must. So we will allocate capital towards biosimilar. And then always looking for specialty portfolio addition. Beyond DHE, we're looking at either a couple of programs internally which we are not ready to discuss yet and working with few outside potential that we can either bring it in-license or buy those products.

    謝謝你,Chris。我們很幸運在平價藥品領域擁有扎實的內生產品線(pipeline)。因此我們在平價藥品以及零售端的學名藥(GX)方面持續布局。我們在吸入劑、眼科、微球等領域擁有領先的產品組合。也包括藥械組合產品。我們擁有非常優秀的產品組合。接著是注射劑,我們還有約12個以上的505(b)(2)注射劑即將推出,包括即用型、胜肽、微球等。我們非常期待。在生物相似藥方面,我們已透過授權引進產品;我們也一直非常坦率地說,這是一個——而且是非常著眼長期的——超過10年的事業,確實如此,我們也已投資很長一段時間。我們需要做到垂直整合。也就是製造在我們手上、研發在我們手上、完整的產品線,以及全球市場。就像在複雜學名藥(complex GX)一樣,我們會長期深耕。我們的使命是成為美國第一的平價藥品公司。因此擴張生物相似藥是必須的。所以我們會把資本配置到生物相似藥。同時也會持續尋找專科產品組合的補強。除了DHE之外,我們也在評估幾個內部專案,目前還不便討論,並與一些外部潛在標的合作,可能透過授權引進或直接收購這些產品。

  • Christopher Schott - Analyst

    Christopher Schott - Analyst

  • Great. Thanks so much.

    很好。非常感謝。

  • Operator

    Operator

  • David Amsellem, Piper Sandler.

    David Amsellem,Piper Sandler。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • Thanks. So I've got a couple. So you cited GLP-1s, peptides in 2028. Are those launches in ex-U.S./emerging markets? Is it Trulicity? Is it comp in the United States? Is it a combination of those things? I'm just trying to get a sense of what you're thinking regarding that 2028 number that's on slide 6. And then secondly, with the Metsera collaboration, you're constructing the new facilities. But you've also talked about beyond peptides vertically integrating your biosimilar business. And so I guess my question here is how should we think about growth in CapEx over the next several years? And how that plays into your overall debt paydown strategy because it sounds like there's significant expansion of your infrastructure that's going to be happening. So just wanted to get your thoughts there. I'll leave it there. Thanks.

    謝謝。我有幾個問題。你提到 2028 年的 GLP-1、胜肽。那些上市是發生在美國以外/新興市場嗎?是 Trulicity 嗎?是在美國的競品嗎?還是以上幾種的組合?我只是想了解你們對投影片 6 上那個 2028 年數字的思考。第二個問題,關於與 Metsera 的合作,你們正在興建新設施。但你們也談到除了胜肽之外,會把生物相似藥業務做垂直整合。所以我的問題是,未來幾年資本支出(CapEx)的成長應該如何看待?以及這會如何影響你們整體的償債策略,因為聽起來你們的基礎設施將會有顯著擴張。想聽聽你們的看法。我就先問到這裡。謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, David. So first question on GLP-1 by 2028, all of the above, what you mentioned, ex-U.S., could have a product like Trulicity, could have other contract manufacturing business. So that is how we see the GLP-1 through our partnership with Metsera. The growth in CapEx, as we had laid out, Metsera is contributing $100 million. We expect government incentives to be around $100 million. We're investing $100 millio, $150 million of our CapEx over three years. So it's manageable CapEx. As you would have noticed, we increased our CapEx projection for this year about $100 million.

    謝謝你,David。先回答 2028 年 GLP-1 的問題:你提到的情況都有可能,包括美國以外市場、可能有像 Trulicity 這樣的產品、也可能有其他委託製造(CMO)業務。這就是我們透過與 Metsera 的合作夥伴關係所看到的 GLP-1 機會。至於資本支出(CapEx)的成長,如我們先前所說,Metsera 會出資 1 億美元。我們預期政府補助約 1 億美元。我們將在三年內投入約 1 億到 1.5 億美元的 CapEx。所以這是可控的 CapEx。你也會注意到,我們把今年的 CapEx 預估上調了約 1 億美元。

  • We're not on biosimilars. We're not going to start building from scratch. We're going to do certain M&A to bring the capacity already there and pipeline that is already there. And it will require incremental CapEx for those. But we do not know exactly how much. But you can see, in the ballpark, we will continue to be $70 millio, $100 million ongoing on CapEx. But our EBITDA keeps going up, our cash flow is improving, our interest expense is coming down. So no problem. (inaudible) invest here and keep making -- we have the awesome infrastructure already for many things, and this will be additional, a great infrastructure to have.

    至於生物相似藥,我們不是要從零開始建。我們不會從頭開始建置。我們會透過某些併購(M&A)來取得既有的產能與既有的產品管線。這些會需要額外的 CapEx。但我們目前還不知道確切金額。不過你可以看到,大致上我們的 CapEx 會持續維持在每年約 7,000 萬到 1 億美元的水準。但我們的 EBITDA 持續上升、現金流改善、利息費用下降。所以沒有問題。(聽不清)在這裡投資並持續推進——我們已經有很棒的基礎設施可用於很多事情,而這將是額外的、很值得擁有的基礎設施。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • If I may just ask a quick follow-up regarding M&A, do you think that -- in terms of capacity, help us understand how large you can go or what you're thinking about aspirationally in terms of sizing?

    如果可以的話,我想就併購(M&A)再追問一下:就產能而言,能否幫我們理解你們規模可以做到多大,或你們在理想情況下對規模的想法是什麼?

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Well David, we are focused, as Tasos said, we're not going to be -- we'll be 4 times leveraged, under 4 times. And over time, we want to go to 3 times. So we would have to find a creative deal may include the cash-on-hand or limited cash, equity, so there's multiple ways to do it.

    David,我們的重點是——如 Tasos 所說——我們不會讓槓桿太高;我們會維持在 4 倍以下。隨著時間推進,我們希望降到 3 倍。所以我們必須找到有創意的交易方式,可能包含動用手上現金或少量現金、股權等,有多種方式可以做。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • This is Tasos. Just going to be clear, right? Continued leverage and organic revenue growth continues to be our top two priorities, number one. Number two, we're not the big M&A shop. We're not the big M&A shop. The last deal we did which was a $300-some million deal, that was the (inaudible) five years ago. And I think universally, that has paid for itself 5 times over. And it's the strength of our organic pipeline that puts us in a position, I think, to do the right deal that makes sense financially, number one. Number two, it has to be strategic in nature such as biosimilars. And number three, we have a high degree of confidence of executing well. And I think, the way the teams have executed in terms of growing our biosimilars, essentially from nothing three years ago, to something that probably in 2025 this year is probably going to be a $150-some million business, I think that's remarkable. So that's how we think about it. So hopefully, that's helpful.

    我是 Tasos。我想講清楚,對吧?持續去槓桿以及有機營收成長,仍然是我們最優先的兩件事,第一。第二,我們不是大型併購(M&A)玩家。我們不是大型併購玩家。我們上一筆交易大約是 3 億多美元,那是(聽不清)五年前。而且我想大家都同意,那筆交易已經回本超過 5 倍。我們有機產品管線的強勁,使我們有條件去做一筆在財務上合理的正確交易,第一。第二,它必須具有策略性,例如生物相似藥。第三,我們必須對執行有高度信心。我認為,團隊在推動生物相似藥成長方面的執行力——基本上從三年前幾乎是零,到 2025 年今年可能成為約 1.5 億多美元的業務——我覺得這非常了不起。所以我們是這樣思考的。希望這有幫助。

  • David Amsellem - Analyst

    David Amsellem - Analyst

  • It is. Thanks.

    有的。謝謝。

  • Operator

    Operator

  • Les Sulewski, Truist Securities.

    Les Sulewski,Truist Securities。

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Good morning. Thank you for taking my questions. Can you provide any latest commentary around naloxone, any additional contracts that you signed with other states? And then second, haven't really heard much commentary on UNITHROID, maybe provide some puts and takes around long term opportunity there. And then lastly, you did comment on delevering and you deleveraged faster than you anticipated. Is there a new target for 2025? Thank you.

    早安。謝謝讓我提問。你們能否提供關於納洛酮(naloxone)的最新看法,是否與其他州簽了任何新增合約?第二,關於 UNITHROID 幾乎沒聽到太多評論,能否談談其長期機會的利多與利空因素?最後,你們提到去槓桿,而且去槓桿速度比預期更快。2025 年是否有新的目標?謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Good morning, Les. Naloxone, the states are slowing moving. So we haven't -- after California, we're close to a few states. But haven't signed anything new beyond California which was the largest state by far. You have to add another 20 states to get to California. And we're working through the distributors as well who already have the state contracts. So naloxone's moving. It's a three-players market; however, not much in it. So we're emerging and is well-positioned in all these states in longer term contracts. And it is a frustrating process at state level. But we have a team that keeps working on it and we expect to grow this business. But as it is, what we have forecasted, we should be able to provide about 2.5 million kits this year to the market and going up to 4 million kits in 2026. So that's what we're working towards.

    早安,Les。納洛酮方面,各州推進速度正在放慢。所以在加州之後,我們接近幾個州。但除了加州之外——加州迄今為止是最大的州——我們還沒有簽任何新合約。你得再加上另外 20 個州才差不多等於加州。我們也在與經銷商合作,因為他們已經有州政府合約。所以納洛酮正在推進。這是一個三家競爭的市場;不過差距不大。因此我們正在崛起,並且在這些州的長期合約上處於有利位置。但在州政府層級,這是一個令人挫折的流程。不過我們有團隊持續推進,我們預期會成長這項業務。以目前我們的預測,今年我們應可向市場提供約 250 萬套(kits),並在 2026 年提升到 400 萬套。這就是我們努力的方向。

  • UNITHROID is like Synthroid. The patient which favors consistent therapy, and that is what we provide. It has a consistent growth profile over time. We see it going the same way.

    UNITHROID 類似 Synthroid。病患偏好一致性的治療,而這正是我們所提供的。它長期以來呈現穩定的成長曲線。我們預期它會以相同方式發展。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Les, good morning. From deleveraging perspective, you can expect us to continue to pay down debt and reduce net debt-to-EBITDA in 2025. Just depending on the number of scenarios around interest rates, refinancing, et cetera. We're targeting about, give or take, between $80 million to $100 million overall reduction in gross debt, number one. This year in 2024, we finished net debt-to-EBITDA 3.9%. My gut feeling is we're targeting 3.6% to 3.7% net debt-to-EBITDA, so another 0.3% or 0.2% reductions in net debt-to-EBITDA. So we're going to continue going down in a reasonable manner reduction of leverage growth and net debt.

    Les,早安。就去槓桿而言,你可以預期我們在 2025 年會持續償還債務並降低淨負債/EBITDA。這取決於利率、再融資等多種情境。我們的目標是整體總負債(gross debt)減少約 8,000 萬到 1 億美元,第一。2024 年我們的淨負債/EBITDA 結束在 3.9%。我直覺認為我們的目標是淨負債/EBITDA 約 3.6% 到 3.7%,也就是再降低約 0.3% 或 0.2%。所以我們會以合理的方式持續下降,降低槓桿並降低淨負債。

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Great. Thank you for that color.

    很好。謝謝你提供這些補充說明。

  • Operator

    Operator

  • Balaji Prasad, Barclays.

    Balaji Prasad,巴克萊。

  • Balaji Prasad - Analyst

    Balaji Prasad - Analyst

  • Good morning, everyone. So it's great to see the consistent progress and the healthy outlook. I'll try to read a couple of questions on topics, not a lot. But Tasos, starting with you, firstly on the guidance and EBITDA margins, 2025 EBITDA range seems to be at around 20.9% to 22.5%. I'm surprised to see that even at the higher end there is limited (inaudible) expansion. So how much of a drag has RYTARY LOE been on this? And are there any other factors at play? One. Two, I'm sure everyone will be happy to say that's not a big M&A shop and the focus will be on continuing to delever. So is this going to be more of a consistent deliverage year-over-year or are you comfortable with the bump-up in net leverage on the back of any deals?

    各位早安。很高興看到持續一致的進展以及健康的展望。我會試著就幾個主題提兩三個問題,不會太多。不過 Tasos,先從你開始,第一個關於指引與 EBITDA 利潤率,2025 年 EBITDA 區間看起來大約在 20.9% 到 22.5%。我很意外即使在較高端,擴張幅度也有限(聽不清)。所以 RYTARY 專利到期(LOE)對此造成了多大的拖累?還有其他因素在起作用嗎?第一點。第二點,我相信大家都會樂於聽到你們不是一家大型併購(M&A)公司,重點會放在持續去槓桿。那麼這會是逐年穩定去槓桿,還是你們對於因任何交易而導致淨槓桿上升的情況也能接受?

  • Lastly, Chirag, I was just curious, combining your recent approval of limited (inaudible) issues with (inaudible) and that they can't supply, they evidently need a supplier, do you see any scope for you to monetize your approval early either in the form of a supply deal or an accelerated launch out of January 2026? Thank you.

    最後,Chirag,我只是好奇,把你們近期獲得的有限(聽不清)核准問題與(聽不清)以及他們無法供貨的情況結合來看,他們顯然需要供應商;你是否看到你們有機會提前將核准變現,例如透過供應協議,或將原定 2026 年 1 月的上市時程提前加速?謝謝。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Let me take the first couple of them, Balaji, and good morning. So number one is, you're correct, you can look at EBITDA as a percentage of revenue. And in 2024, we were at about 22.5%. You look at the guidance, we're more like 21%. So it looks a bit of a deterioration. I wouldn't read anything into this. This is driven by a couple of things. Number one is it's a mix of business. AvKARE continued to grow faster than the rest of the business. And the simple fact is that business is slightly less profitable than the rest of the business. But frankly, we don't care. We just looking at incremental dollars, right, and incremental cash that can help us fund our business and grow. So that's number one.

    Balaji,我先回答前面幾個問題,早安。第一點,你說得對,你可以把 EBITDA 視為營收的百分比來看。2024 年我們大約是 22.5%。看指引的話,我們更接近 21%。所以看起來像是有些惡化。我不會對此做過度解讀。這主要由幾個因素驅動。第一是業務組合。AvKARE 的成長持續快於其他業務。而事實上,那塊業務的獲利能力略低於其他業務。但坦白說,我們不在意。我們只看增量美元,對吧,以及能幫助我們為業務提供資金並成長的增量現金。這是第一點。

  • And then obviously the combination of the RYTARY LOE, right, RYTARY is a 90% margin product, right? And they need to kind of invest in CREXONT and maximize the slope of growth for that product. So that's what I would say.

    然後很明顯還有 RYTARY 專利到期(LOE)的組合影響,對吧,RYTARY 是一個毛利率 90% 的產品,對吧?而且他們需要在 CREXONT 上投入,並把該產品的成長斜率最大化。所以我會這麼說。

  • My gut feeling is we're barely in 2025. I think as we look at 2026, as we anniversary, most of the RYTARY LOE, the incremental investments, full-year investments of CREXONT begin to level off, I will expect to see EBITDA margin to begin increasing. So that's kind of on that.

    我的直覺是,我們才剛進入 2025 年。我認為當我們看到 2026 年、在基期效應消化後,RYTARY 專利到期(LOE)的大部分影響、以及 CREXONT 的增量投資(全年化投資)開始趨於平緩時,我預期 EBITDA 利潤率會開始上升。大概就是這樣。

  • Number two, on deleveraging, I mean, the company is not on autopilot. So in five years, we reduced leverage from 7.4% to 3.9%. Probably in 2025, we'll get 3.6%. We would like to see in a perfect world a gliding path of reduction. If at any given point in time there is a slight increase for a few months or for a year, I don't think our equity holders or our debt holders will be concerned because it will be the right decision that's going to begin leading to further delevering over the course of time.

    第二點,關於去槓桿,我是說,公司不是在自動駕駛。五年內,我們把槓桿從 7.4% 降到 3.9%。2025 年可能會到 3.6%。在理想情況下,我們希望看到一條平滑下行的降低路徑。如果在任何特定時間點,因為幾個月或一年而出現些微上升,我不認為我們的股東或債權人會擔心,因為那會是正確的決策,並將在一段時間內帶來進一步去槓桿。

  • Chirag, on the other questions?

    Chirag,其他問題呢?

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • I believe it's IP --

    我相信那是智慧財產權(IP)——

  • Jason Daly - Senior Vice President, Chief Legal Officer, Corporate Secretary

    Jason Daly - Senior Vice President, Chief Legal Officer, Corporate Secretary

  • Subject to a settlement, Chirag. And thanks for the question, Balaji. This is Jason Daly, the Chief Legal Officer. Given the settlement dynamics, I think we shouldn't be talking too much about lenalidomide. But obviously, we're excited for all of the products that are in our portfolio and looking forward to launching them all.

    以和解為前提,Chirag。也謝謝你的提問,Balaji。我是 Jason Daly,首席法務長。鑑於和解的相關動態,我想我們不應該過多談論來那度胺(lenalidomide)。但顯然,我們對投資組合中的所有產品都感到振奮,並期待把它們全部推向上市。

  • Operator

    Operator

  • We have no further questions, so I'd like to hand back to Chirag for any closing remarks.

    我們沒有進一步的問題,因此我想把時間交還給 Chirag,請他做任何結語。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Well, thank you very much. Have a nice weekend. Thanks.

    好的,非常感謝。祝各位週末愉快。謝謝。

  • Operator

    Operator

  • This concludes today's call. You may now disconnect from the call and enjoy the rest of your day.

    今天的電話會議到此結束。您現在可以掛線,祝您今天剩餘時間愉快。